Clinical trials: Schizophrenia Spectrum Disorder
Schizophrenia
A Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic Drug
The purpose of this study is to compare the patient satisfaction between continued administration of previous antipsychotics versus switched administration to paliperidone ER in non-satisfied patients with previous (paliperidone)
- Trial name
- NCT01592201
- Testing
- Paliperdidone ER, Aripiprazole, olanzapine and risperidone (Antipsychotics)
- Where
- 9 sites in South Korea
- Volunteers
- 13 people
- Sponsor
- Janssen Korea, Ltd., Korea
Schizophrenia
Bifeprunox in the Treatment of Schizophrenia
Study of the long-term efficacy and safety of bifeprunox in the treatment of schizophrenia. Extension to study S154.3.001.
- Trial name
- NCT00193687
- Testing
- bifeprunox
- Volunteers
- 986 people
- Sponsor
- Solvay Pharmaceuticals
Schizophrenia
INVISION - An Observational Study to Explore Effectiveness, Tolerability and Safety of Paliperidone ER in Patients With Schizophrenia
The purpose of this study is to explore efficacy, tolerability and safety of paliperidone Extended Release (ER) in 250 schizophrenia patients who started treatment with paliperidone ER in a naturalistic setting.
- Trial name
- NCT00697658
- Testing
- Paliperidone ER
- Where
- 17 sites in Netherlands
- Volunteers
- 27 people
- Sponsor
- Janssen-Cilag B.V.
Schizophrenia
A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable Schizophrenia
The purpose of this study is to evaluate safety, tolerability and pharmacokinetics (explores what the body does to the drug) of JNJ-37822681 in participants with stable schizophrenia (psychiatric disorder with symptoms of…
- Trial name
- NCT01812642
- Testing
- JNJ-37822681
- Where
- 6 sites in Belgium, Germany and 3 more
- Volunteers
- 33 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorder
A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents
Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia.
- Trial name
- SWITCHCore (NCT01143077)
- Testing
- Lurasidone HCl
- Where
- 27 sites in United States
- Volunteers
- 244 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia
A 52 Week Open-label Extension Trial Following the Double-blind Efficacy and Safety Study R076477-SCH-305.
Open-Label Extension to the double-blind effectiveness and safety study R076477-SCH-305 to evaluate long-term safety and tolerability in patients with schizophrenia.
- Trial name
- NCT00668837
- Testing
- Paliperidone
- Volunteers
- 407 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizoaffective Disorder
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
This study will evaluate the efficacy of paliperidone palmitate compared with placebo in the delay of relapse of the symptoms of schizoaffective disorder.
- Trial name
- NCT01193153
- Testing
- paliperidone palmitate
- Where
- 80 sites in United States, Bulgaria and 6 more
- Volunteers
- 667 people
- Sponsor
- Janssen Scientific Affairs, LLC
Major Depressive Disorder, Bi-Polar Disorder
DELPhI Evaluation of Psychiatric Conditions
DELPhI acquisition and analysis software, a QuantalX Neuroscience development, which is designed to measure, analyze, and display brain electrical activity of human electroencephalogram (EEG), to transcranial magnetic stimulation…
- Conditions
- Major Depressive Disorder, Bi-Polar Disorder, ADHD, Schizophrenia
- Trial name
- NCT03842345
- Sponsor
- QuantalX Neuroscience
Schizophrenia
Observational Study to Evaluate Efficacy and Remission Status for Schizophrenia Patients Under Atypical Treatment
The objective of this study is to evaluate under routine clinical setting the efficacy and remission status from treatment of 2nd-generation antipsychotic in patients who is upon acute episode or not achieving remission under…
- Trial name
- QTP NIS (NCT00809731)
- Where
- 17 sites in Taiwan
- Volunteers
- 490 people
- Sponsor
- AstraZeneca
Schizophrenia
Safety and Efficacy of Seroquel in First Episode Schizophrenia
To compare the safety, tolerability and efficacy of Seroquel and risperidone in first episode schizophrenia
- Trial name
- NCT00254241
- Testing
- Seroquel and Risperidone
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- AstraZeneca
Schizophrenia
Safety and Tolerability Study of Drug to Treat Schizophrenia
The purpose of this study is to evaluate the long-term safety of SM-13496 in patients with schizophrenia.
- Trial name
- NCT00044005
- Testing
- Lurasidone 20 mg, Lurasidone 40 mg, Lurasidone 80mg
- Where
- 26 sites in United States
- Volunteers
- 98 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia
PK Study of Aripiprazole IM Depot for Chinese Patients With Schizophrenia
This study assess pharmacokinetics and safety of multi-administration of Aripiprazole IM Depot formulation at doses of 400mg in patients with schizophrenia.
- Trial name
- NCT03285503
- Testing
- Aripiprazole IM Depot
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Otsuka Beijing Research Institute
Schizophrenia
Efficacy of Bifeprunox in Patients With Schizophrenia
The primary purpose of the study is to evaluate the efficacy of bifeprunox in the maintenance phase of schizophrenia compared to placebo.
- Trial name
- NCT00658645
- Testing
- Bifeprunox, Quetiapine
- Where
- 38 sites in Bulgaria, China and 6 more
- Volunteers
- 227 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
NIS to Observe Improvement in Global Assessment of Functioning in Patients With Schizophrenia
The purpose of the study is to monitor the general functional changes among patients with schizophrenia, treated with atypical antipsychotics dosed once daily for a period of 6 months.The primary study objective is to compare…
- Trial name
- NCT00833456
- Where
- 14 sites in Slovenia
- Volunteers
- 106 people
- Sponsor
- AstraZeneca
Schizophrenia, Cognition Disorders
The Effect of Nicotine on Arousal, Cognition and Social Cognition in Schizophrenic Patients
This study in patients with stable schizophrenia will investigate the effect of nicotine on arousal, cognitive task and social cognition after acute dose administration.
- Trial name
- NCT01186471
- Testing
- A643 (nicotine)
- Volunteers
- 32 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Schizophrenia
Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia
This research is a Randomized, double-blind, risperidone-controlled, multicenter clinical study. Chinese subjects with Ischemic Schizophrenia.
- Trial name
- NCT02453893
- Testing
- Iloperidone, Risperidone
- Where
- China
- Volunteers
- 288 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Schizophrenia
Efficacy and Safety of Asenapine With Placebo and Haloperidol (41023)(P05926)(COMPLETED)
Schizophrenia is a brain disease. The primary features of schizophrenia are characterized by Positive symptoms (symptoms that should not be there, inability to think clearly, to distinguish reality from fantasy i.e., hearing…
- Trial name
- NCT00156104
- Testing
- Asenapine, Haloperidol
- Volunteers
- 460 people
- Sponsor
- Organon and Co
Schizophrenia, Schizoaffective Disorder
Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.
A Multicenter, Double-blind 16 Week Study on the augmentation of atypical antipsychotic with Aripiprazole in patients with Schizophrenia with inadequate response to antipsychotic treatment.
- Trial name
- NCT00325689
- Testing
- Quetiapine or Risperidone + Aripiprazole
- Where
- 48 sites in United States
- Volunteers
- 323 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Study to Observe the Safety and Tolerability of Paliperidone Palmitate (Invega Sustenna) in Korean Schizophrenic Patients
The purpose of this study is to evaluate the safety and tolerability of paliperidone palmitate over a 9-week period for participants with schizophrenia in Korea.
- Trial name
- NCT01819818
- Testing
- No intervention
- Where
- South Korea
- Volunteers
- 3,267 people
- Sponsor
- Janssen Korea, Ltd., Korea
Schizophrenia
Observe Real-life Allocation of Atypical Antipsychotics in the Acute Inpatient Management of Schizophrenia
The primary objective of this Non- Interventional Study (NIS) is to describe the use of atypical antipsychotics in subjects with Schizophrenia during the hospitalisation due to acute psychotic episode by evaluation of drug, dose…
- Trial name
- RECONNECT-S (NCT01544608)
- Where
- 7 sites in Egypt, Saudi Arabia and 1 more
- Volunteers
- 1,076 people
- Sponsor
- AstraZeneca